GenSight Biologics : Corporate presentation, May 2019

Corporate Presentation

May 2019

A LEADING GENE THERAPY BIOTECHNOLOGY COMPANY

GENSIGHT-BIOLOGICS.COM

Disclaimer

This document contains forward-looking statements and estimates made by the GenSight Biologics S.A. (the "Company"), including with respect to the anticipated future performance of the Company, its subsidiaries and affiliates, and the market in which they operate. They include all matters that are not historical facts. These forward-looking statements can be identified by the use of forward-looking terminology including the terms "developments," "estimates," "expects," "intends," "may," "milestones," "potential," "value," "time to market," "targeting," "on track," "planned," "will," "move to," or other variations or comparable terminology, or by discussions of strategy and funding, as well as the Company's, its subsidiaries' and affiliates' technology, and are based on financial and non-financial information, including projections as to the future regulatory situation and other information and assumptions. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may

depend upon factors that are beyond the Company's control. Therefore, actual results, the financial condition, performance or achievements of the Company, its subsidiaries and affiliates or industry results, may turn out to be materially different from any future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Forward- looking statements, forecasts and estimates only speak as of the date of this forward-looking statement, and no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. The Company, its subsidiaries and affiliates disclaim any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in the Company's expectations with regard thereto, or any events, or changes in conditions or circumstances on which any such statement, forecast or estimate is based.

2 May 2019 - Non-Confidential

Corporate Overview

Clinical-stage gene therapy company

• Focused on severe retinal degenerative pathologies leading to blindness as well as CNS diseases
• Well positioned to advance disruptive gene therapy technologies in ophthalmology to commercialization

Two disruptive technology platforms

• Mitochondrial targeting sequence (MTS)
• Optogenetics

Lead projects target:

• GS010 - Leber Hereditary Optic Neuropathy (Phase III)
• GS030 - Retinitis pigmentosa and dry-AMD (Phase I/II)

Listed on Euronext Paris (SIGHT)

• Established in 2012, IPO in July 2016 (EUR45m)
• GenSight Biologics Inc incorporated in the US in May 2017

3 May 2019 - Non-Confidential

Executive Team

Bernard Gilly

Chief Executive Officer

PIXIUM VISION (Since 2011) Chairman of the Board, Founder

FOVEA PHARMA (2005-2009)Chairman & CEO - sold to Sanofi

SOFINNOVA PARTNERS (2000-2005)Managing Partner

TRANSGENE (1992-2000) Chairman & CEO

Ph.D. in biology and bio-economics

4 May 2019 - Non-Confidential

Thomas Gidoin

Chief Financial Officer

DBV TECHNOLOGIES (2012-2015)

VP of Finance

IPSEN (2008-2011)

UK Operations Controller (London)

Senior Financial Analyst (Paris)

ERNST & YOUNG (2007-2008)

Auditor

Barrett Katz

Chief Medical Officer

MONTEFIORE MED CENTER & A. EINSTEIN COLLEGE OF MEDICINE, NY, USA (2011-2017)

Prof. of Ophthalmology, Neurology and Neurosurgery

DANUBE PHARMA (2009-2011)

CEO

FOVEA PHARMA(2007-2009)

CMO

EYETECH (2005-2007)

VP of Medical Affairs andStrategy

MD, Board-certified ophthalmologist & neurologist

Our target: degenerative retinal diseases with underlying genetic causes

 Unmet need: high

LEBER HEREDITARY OPTIC

NEUROPATHY (LHON)

1. Degeneration of RGCs	1

• Inexorable progression to blindness for most patients
• No approved treatments*

 The eye: an ideal laboratory

Genetic mutations	• Immune-privileged, closed system
Aging	• Intravitreal injections to introduce of genetic
material close to target cells
	• Slow turnover of retinal cells support long-
	term expression of transduced genes

	2. Degeneration of photoreceptors	2	 AAV: proven vector for gene therapy
RETINITIS PIGMENTOSA (RP)	•	Proven safety and proof of effect in humans
			•	Efficient transduction of retinal cells
GEOGRAPHIC ATROPHY		•	No need to screen patients for Nab before
(Late stage form ofAge-Related		•	treatment
Macular Degeneration - AMD)		Validated manufacturing process

	Source: Company
5 May 2019 - Non-Confidential	*Except for exceptional circumstances for idebenone in Europe